amphetamine has been researched along with am 251 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiou, LC; Gean, PW; Huang, YC; Wang, SJ | 1 |
| Caraballo, I; El Banoua, F; Fernandez-Espejo, E; Ferrer, B; Flores, JA; Galan-Rodriguez, B; Rodriguez de Fonseca, F | 1 |
| Di Marzo, V; Hasenöhrl, RU; Molleman, A; Thiemann, G | 1 |
| Advani, T; Cassano, T; Giuffrida, A; Hensler, JG; Seillier, A | 1 |
| Bouchard, C; Ducrot, C; Fortier, E; Gallo, A; Rompré, PP | 1 |
5 other study(ies) available for amphetamine and am 251
| Article | Year |
|---|---|
Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala.
Topics: Amphetamine; Amygdala; Animals; Arachidonic Acids; Benzoxazines; Calcium; Calcium Channels; Central Nervous System Stimulants; Dopamine Antagonists; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; In Vitro Techniques; Ligands; Long-Term Synaptic Depression; Male; Morpholines; Naphthalenes; Patch-Clamp Techniques; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Synaptic Transmission | 2003 |
Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function.
Topics: Acyltransferases; Amidohydrolases; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Arachidonic Acids; Behavior, Animal; Brain Chemistry; Cell Count; Central Nervous System Stimulants; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Endocannabinoids; Functional Laterality; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Wistar; Rotation; Serotonin Antagonists; Serotonin Receptor Agonists; Substantia Nigra; Tyrosine 3-Monooxygenase | 2004 |
The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus.
Topics: Amphetamine; Animals; Behavior, Animal; Biogenic Monoamines; Dopamine; Hippocampus; Hydroxyindoleacetic Acid; Male; Mice; Motor Activity; Nucleus Accumbens; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Serotonin | 2008 |
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
Topics: Amidohydrolases; Amphetamine; Animals; Autoradiography; Behavior, Animal; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Central Nervous System Stimulants; Cyclohexanols; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Guanosine 5'-O-(3-Thiotriphosphate); Hallucinogens; Interpersonal Relations; Male; Memory, Short-Term; Motor Activity; Neuropsychological Tests; Phencyclidine; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Statistics, Nonparametric; Sulfur Isotopes; Time Factors | 2010 |
Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Benzoxazines; Brain; Brain Injuries; Central Nervous System Stimulants; Conditioning, Operant; Disease Models, Animal; Dronabinol; Female; Hippocampus; Male; Morpholines; Motivation; Naphthalenes; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Reward; Schizophrenia; Self Administration; Time Factors | 2014 |